Table 5 Average posteriors of individual-level coefficients and relative treatment effects by HIL subgroup
All | Low HIL | High HIL | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | Treatment 1 | Treatment 2 | Treatment 1 | Treatment 2 | |||||
Model B (alternative to status quo) | -1.587 | -1.614 | -1.411 | |||||||
+ 9.3% | + 19.6% | + 19.4% | + 25.7% | + 7.9% | + 12.9% | |||||
(2.4%) | (2.5%) | (7.3%) | (7.6%) | (7.2%) | (7.5%) | |||||
VBID elements | ||||||||||
Copayment | 0% high-value care | 0.570 | 0.561 | 0.572 | ||||||
-44.2% | -44.1% | -45.0% | -44.8% | -38.2 | -40.2% | |||||
(1.2%) | (0.8%) | (3.5%) | (2.5%) | (3.8%) | (3.2%) | |||||
20% low-value care | -0.982 | -0.941 | -1.002 | |||||||
-30.6 | -31.5% | -36.9 | -46.3% | -29.9% | -28.8% | |||||
(2.7%) | (3.0%) | (9.5%) | (10.1%) | (8.1%) | (8.9%) | |||||
Drug disbursement based on value | -0.909 | -0.919 | -0.925 | |||||||
+ 21.8% | + 17.7% | + 25.1% | + 20.5% | + 21.4% | + 17.3% | |||||
(0.8%) | (0.7%) | (2.4%) | (2.2%) | (2.3%) | (2.0%) | |||||
General cost-sharing | ||||||||||
Deductible | CHF 0 | 1.178 | 1.141 | 1.152 | ||||||
-20.6% | -1.3% | -14.4% | + 6.3 | -25.2% | -8.3% | |||||
(1.8%) | (1.8%) | (5.7%) | (6.1%) | (5.3%) | (5.4%) | |||||
CHF 5000 | -4.178 | -4.198 | -4.238 | |||||||
+ 0.0 | -16.6% | + 6.4 | -12.9% | -1.6 | -16.9% | |||||
(1.1%) | (1.3%) | (4.0%) | (4.3%) | (3.3%) | (3.7%) | |||||
Monthly premium | -0.034 | -0.037 | -0.033 | |||||||
-2.8 | -3.4% | -3.6% | -2.7% | -2.5 | -2.6% | |||||
(1.9%) | (1.9%) | (5.9%) | (6.3%) | (6.3%) | (6.4%) | |||||